Cancer immunotherapy T cells get a ride – Nature.com
Nature.com |
Cancer immunotherapy T cells get a ride
Nature.com Strategies that inhibit the immune checkpoint blockade (ICB) and reactivate T cells using monoclonal antibodies against programmed cell death protein 1 (PD1) and PD1 ligand 1 (PDL1) have been used to successfully treat immunogenic tumours, and recent … |
